Company intelligence / Profile preview

Boyalife

Wuxi, Jiangsu, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Boyalife demonstrates strong revenue growth (30% YoY in 1H 2025, $44.6M) in cell-processing but continues to face operating losses; ongoing clinical development in regenerative medicine, stem cells, CAR-T, and targeted therapies[1].

Therapeutic areas: CardiovascularInfectious DiseasesMetabolic DisordersOtherOncology
Modalities: Stem cell therapyCAR-T cell therapyGene therapySmall moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Cesca/ThermoGenesis Holdings[4]Science Magazine/AAAS (Stem Cell and Regenerative Medicine Award)[5]Sooam Biotech (animal cloning JV)[6]HealthBanks Biotech[8]

Beyond the preview

Go deeper on Boyalife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boyalife.

Explore the full profile